CN116492282A - Application of lactobacillus sanfranciscensis in preparation of product for resisting oral pathogenic bacteria infection - Google Patents
Application of lactobacillus sanfranciscensis in preparation of product for resisting oral pathogenic bacteria infection Download PDFInfo
- Publication number
- CN116492282A CN116492282A CN202310566338.2A CN202310566338A CN116492282A CN 116492282 A CN116492282 A CN 116492282A CN 202310566338 A CN202310566338 A CN 202310566338A CN 116492282 A CN116492282 A CN 116492282A
- Authority
- CN
- China
- Prior art keywords
- oral
- pathogenic bacteria
- lactobacillus sanfranciscensis
- lactobacillus
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186868 Lactobacillus sanfranciscensis Species 0.000 title claims abstract description 60
- 235000013864 Lactobacillus sanfrancisco Nutrition 0.000 title claims abstract description 60
- 244000052616 bacterial pathogen Species 0.000 title claims abstract description 49
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 8
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 12
- 241000605862 Porphyromonas gingivalis Species 0.000 claims abstract description 11
- 241000186046 Actinomyces Species 0.000 claims abstract description 9
- 241000605986 Fusobacterium nucleatum Species 0.000 claims abstract description 9
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 8
- 244000052769 pathogen Species 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims description 14
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000253 Denture Cleanser Substances 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940051866 mouthwash Drugs 0.000 claims description 2
- 229940041678 oral spray Drugs 0.000 claims description 2
- 239000000668 oral spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000551 dentifrice Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 241000606750 Actinobacillus Species 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 210000000214 mouth Anatomy 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 206010006326 Breath odour Diseases 0.000 abstract description 3
- 208000032139 Halitosis Diseases 0.000 abstract description 3
- 201000007100 Pharyngitis Diseases 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 208000020670 canker sore Diseases 0.000 abstract description 3
- 208000001277 chronic periodontitis Diseases 0.000 abstract description 3
- 201000001245 periodontitis Diseases 0.000 abstract description 3
- 241000193403 Clostridium Species 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 241000588769 Proteus <enterobacteria> Species 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011482 antibacterial activity assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004334 fluoridation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to application of lactobacillus sanfranciscensis in preparing an oral pathogen infection resistant product. The product for resisting oral pathogenic bacteria infection is a product for inhibiting clostridium nucleatum, porphyromonas gingivalis, streptococcus mutans, praecox intermedia and actinomyces conglomerate. The product has a content of Lactobacillus sanfranciscensis of 10 6 ～10 10 cfu/mL. The invention discloses the lactobacillus sanfranciscensis for the first time with the function of inhibiting oral diseasesEffect of primordial infection. Experiments show that lactobacillus sanfranciscensis has good antibacterial property on various common oral pathogenic bacteria such as fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, praecox intermedia, actinobacillus conglomerates and the like, can play a remarkable role in preventing, resisting or eliminating common pathogenic bacteria in the oral cavity, has the functions of inhibiting the growth of the oral pathogenic bacteria and inhibiting the formation of biological films, and can effectively solve a series of oral problems such as halitosis, canker sore, chronic pharyngitis, periodontitis and the like.
Description
Technical Field
The invention relates to application of lactobacillus sanfranciscensis in preparation of products for resisting oral pathogenic bacteria infection, and belongs to the technical field of microorganisms.
Background
The oral cavity contains a large and complex microbial community which is adhered to hard tissues or soft tissues of the oral cavity in a form of a biological film, and the microbial community may be changed along with changes of oral environments such as growth of individuals and tooth growth, and may be different according to eating habits of individuals or families, but generally contains pathogenic bacteria. Oral pathogenic bacteria infection is easy to cause a series of oral problems such as halitosis, canker sore, chronic pharyngitis, periodontitis and the like, and various oral pathogenic bacteria including helicobacter pylori, proteus intermedia, porphyromonas pulposus, streptococcus mutans and the like, different pathogenic bacteria can cause different oral problems, and the pathogenic bacteria of the same oral problem can also be different.
Probiotics are useful as microbial agents that when ingested in sufficient amounts can exert beneficial effects on human health. The common oral probiotics at present are mainly lactobacillus and bifidobacterium, and the antibacterial effects of different types of probiotics can be different. In view of the specific antimicrobial effect of probiotics, existing microbial preparations with probiotics as active ingredient are generally used for combating a specific pathogen or a specific class of pathogens. For example, studies have shown that Streptococcus sanguis, streptococcus mitis and Streptococcus salivarius have an inhibitory effect on the colonization of epithelial cells by Actinobacillus actinomyces in vitro (W.Teughels et al, J Dent Res 86 (7), 611-617, 2007) and can secrete bacteriostatic substances to make pathogenic bacteria weaker or even kill pathogenic bacteria to achieve the efficacy of reducing the number of oral pathogenic bacteria and maintaining oral health. However, to date, only a few strains with maintenance of oral health have been found through experimental procedures.
Lactobacillus sanfranciscensis is an obligate heterofermentative lactic acid bacterium, only the following applications of which are disclosed in the prior art: firstly, lactobacillus sanfranciscensis is used as a starter to prepare flour products; secondly, lactobacillus sanfranciscensis is utilized to prepare products such as ethyl acetate and the like. At present, no report on application of lactobacillus sanfranciscensis to oral pathogen infection is known. Aiming at the deep excavation of the functions of strain resources, the screening of novel probiotic strains with specific functional properties and suitable for the physiological characteristics of Chinese people is particularly important for promoting the development of probiotic products.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides application of lactobacillus sanfranciscensis in preparing a product for resisting oral pathogenic bacteria infection.
The technical scheme of the invention is as follows:
use of lactobacillus sanfranciscensis for preparing a product for resisting oral pathogenic bacteria infection.
According to a preferred embodiment of the present invention, the Lactobacillus sanfranciscensis is Lactobacillus sanfranciscensis Ls-1001, lactobacillus sancensis Bj2 or Lactobacillus sancensis Hw; the preservation number of the old Jin Shanru bacillus Ls-1001 is CGMCC No.14232; the preservation number of the lactobacillus sanfranciscensis Bj2 is CCTCC NO: M2022514; the preservation number of the lactobacillus sanfranciscensis Hw is CCTCCNO: M2022513.
Further preferably, the lactobacillus sanfranciscensis is lactobacillus sanfranciscensis Ls-1001, and the preservation number is CGMCCNo.14232.
According to a preferred embodiment of the invention, the oral pathogenic bacteria are Fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, proteus intermedia or Agrobacter actinomyces.
According to the invention, preferably, the product against oral pathogenic bacteria infection contains lactobacillus sanfranciscensis as the main active ingredient.
According to the invention, the content of Lactobacillus sanfranciscensis in the product for resisting oral pathogenic bacteria infection is preferably 10 6 ～10 10 cfu/mL。
Further preferably, the content of Lactobacillus sanfranciscensis in the product for resisting oral pathogenic bacteria infection is 10 10 cfu/mL。
Preferably, according to the invention, the article of manufacture against infection by oral pathogenic bacteria further comprises at least one carrier.
According to the invention, preferably, the product for resisting oral pathogenic bacteria infection is daily chemical product or medical preparation.
Further preferably, the daily chemical product is toothpaste, tooth cleaning powder or mouthwash.
Further preferred, the medical formulation is an oral spray, a fluoridation agent, a denture cleanser, an oral effervescent tablet, a chewing tablet or an oral dressing.
The invention has the beneficial effects that:
the invention discloses that lactobacillus sanfranciscensis has the effect of inhibiting oral pathogenic bacteria infection for the first time. Experiments of the inventor show that lactobacillus sanfranciscensis has good antibacterial property on various common oral pathogenic bacteria such as clostridium nucleatum, porphyromonas gingivalis, streptococcus mutans, proteus intermedius, actinobacillus conglobatus and the like, can play a remarkable role in preventing, resisting or eliminating common pathogenic bacteria in the oral cavity, has the functions of inhibiting the growth of the oral pathogenic bacteria and inhibiting the formation of biological films, and can effectively solve a series of oral problems such as halitosis, canker sore, chronic pharyngitis, periodontitis and the like.
Detailed Description
For the purposes of clarity, technical solutions and advantages of the present application, the following detailed description will be provided with reference to specific embodiments. The embodiments described herein are only some of the embodiments of the present application and should not be construed as limiting the scope of the present application. The experimental techniques and experimental methods used in this example are conventional techniques unless otherwise specified. Materials, reagents, etc. used in this example are available from regular commercial sources unless otherwise specified.
The preservation number of the old Jin Shanru bacillus Ls-1001 is CGMCC No.14232, which is disclosed in the Chinese patent document CN108102974A and does not relate to strain preservation. The preservation number of the Lactobacillus san francisco Bj2 is CCTCCNO: M2022514, which is disclosed in the Chinese patent document CN115500454A and does not relate to the strain preservation. The preservation number of the lactobacillus sanfranciscensis Hw is CCTCC NO: M2022513, which is disclosed in the Chinese patent document CN115500454A and does not relate to strain preservation. The lactobacillus san francisco is sold by Ningbo biotechnology limited company under the product number B336078.
EXAMPLE 1 inhibition of oral pathogenic bacterial Activity by Lactobacillus sanfranciscensis
1. Inoculating frozen Lactobacillus sanfranciscensis Ls-1001, lactobacillus sanfranciscensis Bj2 and Lactobacillus sanfranciscensis Hw into mMRS liquid culture medium, respectively, and culturing in anaerobic incubator (N) at 30deg.C 2 ∶CO 2 ∶O 2 =79:20:1) for 48h, and activating for 2-3 times for standby. Inoculating the activated bacterial liquid into an mMRS culture medium according to the volume fraction of 1%, and culturing for 24 hours at 30 ℃ to obtain a fermentation liquid. Centrifuging the fermentation broth at 5000r/min for 5min, discarding supernatant, and collecting precipitate to obtain lactobacillus sanfranciscensis thallus. Re-spinning the thallus with sterilized deionized water to obtain lactobacillus sanfranciscensis with content of 10 6 cfu/mL、10 8 cfu/mL and 10 10 cfu/mL of lactobacillus sanfranciscensis suspension to obtain a sample to be tested.
Composition of mrs medium: 10g/L of peptone, 5g/L of yeast extract powder, 10g/L of beef extract powder, 20g/L of maltose, 5g/L of sodium acetate, 2g/L of dipotassium hydrogen phosphate, 2g/L of ammonium citrate, 0.2g/L of magnesium sulfate, 0.05g/L of manganese sulfate, 1mL/L of tween 80 and pH value of 5.4.
2. Determination of oral pathogenic bacteria inhibition Activity of Lactobacillus sanfranciscensis
Antibacterial activity assay using a filter paper sheet method: the filter paper sheet is soaked in lactobacillus sanfranciscensis suspension for 1 hour and then is placed in a sterile environment for airing for standby. The oral pathogenic bacteria (Fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, proprietas intermedia and Actinobacillus actinomyces) cultured to the logarithmic growth phase are respectively diluted to 655nm absorbance of 0.2 by using BHI broth, then 0.1mL of the prepared oral pathogenic bacteria suspension is respectively added into solid BHI culture medium, the oral pathogenic bacteria suspension is uniformly coated by a coating rod, the dried filter paper is placed at the corresponding position, and meanwhile, the filter paper soaked by sterile water is used as a blank control. Culturing at 36+ -1deg.C for 48h. The size of the inhibition zone was measured and the average value was taken in parallel experiments, and the results are shown in table 1.
TABLE 1
As is clear from Table 1, the old Jin Shanru bacterium Ls-1001, the old Lactobacillus delbrueckii Bj2 and the old Lactobacillus delbrueckii Hw all have obvious inhibition effect on the oral pathogenic bacteria Fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, proprietas intermedia and Actinobacillus actinomyces, wherein the old Jin Shanru bacterium Ls-1001 has the strongest inhibition capability on pathogenic bacteria of each oral cavity, and the optimal use concentration of the old Jin Shanru bacterium Ls-1001 is 10 10 cfu/mL。
EXAMPLE 2 inhibition of oral pathogenic biofilm formation by Lactobacillus sanfranciscensis
1. A Lactobacillus sanfranciscensis suspension was prepared as described in example 1.
2. Assay for inhibiting oral pathogenic bacteria biofilm formation by lactobacillus sanfranciscensis
Respectively diluting oral pathogenic bacteria (Fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, proprietas intermedia and Actinobacillus actinomyces) cultured to logarithmic phase with BHI broth until the absorbance at 655nm is 0.2, taking sterilized 96-well cell culture plate, adding 100 μl of Lactobacillus sanfranciscensis suspension and 100 μl of oral pathogenic bacteria suspension into plate hole, and culturing at 37deg.C for 48 hr; sucking out the culture solution and suspended bacteria, leaving only the formed biofilm, flushing the biofilm in the holes with sterile distilled water for 3 times, and adding 0.4wt% crystal violet into the holes to dye the biofilm for 15min; washing the dyed biological film in the hole with sterile water for 4 times to remove unbound crystal violet, and drying at 37 ℃ for 2 hours; adding 100 mu L of 95% ethanol solution into each hole, shaking the plate for 10min to release pigment in the biological film into ethanol, and testing absorbance; the absorbance of the control group to which only sterile water was added was taken as 100%, and the test results are shown in table 2 below.
TABLE 2
As is clear from Table 2, the strain of Bacillus dysarius LS-1001 and Lactobacillus delbrueckiiThe bacterium Bj2 and the lactobacillus sanfranciscensis Hw have obvious inhibition effects on the formation of oral pathogenic bacteria Fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, proprietas intermedia and actinomycetes conglomerate biological films, and the more obvious the inhibition effect on the formation of oral pathogenic bacteria biological films is along with the increase of the concentration of the lactobacillus sanfranciscensis, 10 of the bacteria 10 cfu/mL of Lactobacillus sanfranciscensis Hw has the best effect of inhibiting the formation of oral pathogenic bacteria biofilm.
EXAMPLE 3 removal of oral pathogenic bacteria biofilm by Lactobacillus sanfranciscensis
1. A Lactobacillus sanfranciscensis suspension was prepared as described in example 1.
2. Determination of oral pathogen biofilm removal by lactobacillus sanfranciscensis
Diluting oral pathogenic bacteria (Fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, proprietas intermedia and Acinetobacter actinomyces) cultured to logarithmic phase with BHI broth until the absorbance is 0.2 at 655nm, adding 100 mu L of oral pathogenic bacteria suspension into wells of a 96-well cell culture plate, culturing at 37 ℃ for 48 hours until a biological film is formed, and adding 100 mu L of Lactobacillus sanfranciscensis suspension into each well; after 20min of incubation at 37 ℃, the broth and suspended bacteria were removed, only the biofilm remained in the wells, the biofilm in the wells was rinsed 3 times with sterile distilled water, and 0.4wt% crystal violet was added to the wells to dye the biofilm for 15min; washing the dyed biological film in the hole with sterile water for 4 times to remove unbound crystal violet, and drying at 37 ℃ for 2 hours; adding 100 mu L of 95% ethanol solution into each hole, shaking the plate for 10min to release pigment in the biological film into ethanol, and testing absorbance; the absorbance of the control group to which only sterile water was added was taken as 100%, and the test results are shown in table 3 below.
TABLE 3 Table 3
As is clear from Table 3, the old Jin Shanru bacterium Ls-1001, the old Lactobacillus sanfranciscensis Bj2 and the old Lactobacillus sanfranciscensis Hw can remove oral pathogenic bacteria Fusobacterium nucleatum, porphyromonas gingivalis and Proteus variansThe formed biofilm of Streptococcus mutans, proteus intermedia and Agrobacterium actinomyces became more remarkable, and the biofilm removal ability was more remarkable with the increase in the concentration of Lactobacillus sanfranciscensis, 10 of them 10 cfu/mL of Lactobacillus sanfranciscensis Ls-1001 has the best effect of removing oral pathogenic bacteria biofilm.
Claims (10)
1. Use of lactobacillus sanfranciscensis for preparing a product for resisting oral pathogenic bacteria infection.
2. The use according to claim 1, wherein the lactobacillus sanfranciscensis is lactobacillus sanfranciscensis Ls-1001, lactobacillus sancensis Bj2 or lactobacillus sancensis Hw; the preservation number of the old Jin Shanru bacillus Ls-1001 is CGMCC No.14232; the preservation number of the lactobacillus sanfranciscensis Bj2 is CCTCC NO: M2022514; the preservation number of the lactobacillus sanfranciscensis Hw is CCTCC NO: M2022513.
3. The use according to claim 2, wherein the lactobacillus sanfranciscensis is lactobacillus sanfranciscensis Ls-1001 with a preservation number of CGMCC No.14232.
4. The use according to claim 1, wherein the oral pathogenic bacteria are fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, praecox intermedia or actinomyces conglomerate.
5. The use according to claim 1, wherein lactobacillus sanfranciscensis is used as the main active ingredient in the preparation for combating oral pathogenic bacteria infection.
6. The use according to claim 1, wherein the content of lactobacillus sanfranciscensis in the product against oral pathogenic bacteria infection is 10 6 ～10 10 cfu/mL。
7. The use according to claim 1, wherein the oral pathogen infection resistant product comprises lactobacillus sanfranciscensisIn an amount of 10 10 cfu/mL。
8. The use of claim 1, wherein the article of manufacture for combating oral pathogenic bacterial infections further comprises at least one carrier.
9. The use according to claim 1, wherein the article resistant to infection by oral pathogenic bacteria is a daily chemical or medical preparation.
10. The use of claim 9, wherein the daily chemical product is a toothpaste, a dentifrice or a mouthwash; the medical preparation is an oral spray, a fluorine coating agent, a denture cleanser, an oral effervescent tablet, a chewing tablet or an oral dressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310566338.2A CN116492282A (en) | 2023-05-19 | 2023-05-19 | Application of lactobacillus sanfranciscensis in preparation of product for resisting oral pathogenic bacteria infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310566338.2A CN116492282A (en) | 2023-05-19 | 2023-05-19 | Application of lactobacillus sanfranciscensis in preparation of product for resisting oral pathogenic bacteria infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116492282A true CN116492282A (en) | 2023-07-28 |
Family
ID=87318279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310566338.2A Pending CN116492282A (en) | 2023-05-19 | 2023-05-19 | Application of lactobacillus sanfranciscensis in preparation of product for resisting oral pathogenic bacteria infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116492282A (en) |
-
2023
- 2023-05-19 CN CN202310566338.2A patent/CN116492282A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012203217B2 (en) | Methods and means for protecting the skin against pathogenic microorganisms | |
| CA1262442A (en) | Anticariogenic or antiperiodontitic agent | |
| JP5365166B2 (en) | Oral composition containing lactic acid bacteria | |
| Lee et al. | Antimicrobial activity of Bifidobacterium spp. isolated from healthy adult Koreans against cariogenic microflora | |
| NO316644B1 (en) | Lactobacillus strains of human origin, mixtures and their use | |
| Maripandi et al. | Prevalence of dental caries bacterial pathogens and evaluation of inhibitory concentration effect on different tooth pastes against Streptococcus spp | |
| DK2555785T3 (en) | Use of Streptococcus salivarius in the treatment of chronic respiratory tract infections | |
| KR20160087372A (en) | Cosmetic composition for prevention and improvement of vaginosis | |
| TW202118498A (en) | Composition and vaginal cleaning composition for inhibiting of vaginal pathogens and uses thereof | |
| KR20220139280A (en) | NOVEL STRAIN OF Lactobacillus plantarum AND COMPOSITION FOR PREVENTING OR TREATING OF INFLAMMATORY DISEASE USING THE SAME | |
| MX2012010988A (en) | Use of iminocyclitols as inhibitors of bacterial adherence to epithelial cells. | |
| KR20200129695A (en) | Fermented product of Glehnia littoralis extract, preparation method and use thereof | |
| TWI750716B (en) | Topical composition and its use for preparation of composition for improving skin disease and dermatitis | |
| KR102226187B1 (en) | Lactobacillus iners AHC2030 and Fermented Product Manufactured Using Thereof | |
| KR20210154341A (en) | Disinfectant composition comprising Lactobacillus plantarum culture medium | |
| Ambade et al. | Antimicrobial and antibiofilm activity of essential oil of Cymbopogon citratus against oral microflora associated with dental plaque | |
| CN117264806A (en) | Wettman's bacterium coagulans and application thereof in inhibiting oral pathogenic bacteria | |
| CZ2014565A3 (en) | Lactobacillus strains producing substances that are effective against vaginal pathogens, their use and sanitary means comprising tehreof | |
| CN116492282A (en) | Application of lactobacillus sanfranciscensis in preparation of product for resisting oral pathogenic bacteria infection | |
| CN114317617B (en) | Preparation method and application of triple probiotics fermentation compound with anti-wrinkle effect | |
| CA3018035A1 (en) | Lactic acid bacterial composition for the treatment of bacterial vaginal infections by gardnerella vaginalis and, if present, of concurrent fungal infections | |
| KR102468908B1 (en) | Cosmetic composition for Anti-oxidative or Anti-inflammatory comprising the Fermented extract Stems and Leaf of Watermelon | |
| TWI733207B (en) | Lactobacillus plantarum strain, composition comprising the same, method of producing the same and its use for inhibiting or reducing oral pathogens | |
| KR102199934B1 (en) | Cosmetic compositions containing Hwangryunhaedoktang fermented with Lactobacillus plantarum WiKim0111 for anti-acne | |
| JPH0452249B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |